Home » News
Celprogen Introduced Novel Small Molecules CEP2005 & CEP2010 That Activate and Stimulate Human Cardiac Stem Cells for Repair of Heart Tissue after a Cardiac Arrest

 December 09, 2015 08:52 PM Eastern Standard Time

TORRANCE, Calif.--()--Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have synthesized two small molecules that are able to activate the resident cardiac stem cell pool to accelerate cardiac repair after a Cardiac Arrest. The actual mechanism of action is not yet worked out, but the molecular recruitment of cardiac stem cells is well documented and established in their in-house 3D human cardiac cell culture models. These molecules are being presented at the Annual Cell Biology Meeting in San Diego on Dec. 14, 2015 at B1410, 1:30PM to 3:00PM, Location: ASCB Learning Center, Exhibit Halls D-H, San Diego Convention Center. The gene expression profile of cardiac stem cell markers were increased 5-6 folds above non treated hearts in 3D culture system and also in-vivo mouse and rat models. The abstract is titled: “Novel 3D Primary Human Cardiomyocyte Culture System for Evaluation of Candidate Drug Related Cardiac Safety Profile.”

The present invention relates to administrating these small molecules after a cardiac arrest and then observing the recovery of the heart tissue in returning to baseline cardiac activity. The tissues that received the molecules were able to reach stabilization faster within 24-72 hours when compared to the control group that took 14 to 28 days. The delivery and the mechanism of action are being worked out at present. These synthetic molecules so far have not shown any adverse events in our limited (n=20) in-vivo model systems.

About Celprogen Inc.
Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing a proprietary portfolio of unique therapeutics products and life science research tools that includes genetic engineering technologies, stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in Torrance, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell, Cancer Stem Cell and Primary Cell Culture products to serve our global community. Additional information about Celprogen is available at http://www.celprogen.com.

 

Contacts

Celprogen Inc.
Jay Sharma, 310-575-7759
info@celprogen.com
www.celprogen.com

Back to News Listing